DermTech 2.0 Expands DermTech Stratum™, a Non-Invasive Skin Genomics Service Offering
The DermTech Stratum platform and service offerings are appropriate for indications where skin is the target or a surrogate target organ. They are being used to support drug discovery and development focused on cancers and inflammatory diseases in clinical research studies. DermTech Stratum services have been trusted by over 30 pharma and research partners.
"We are excited to announce this next stage of DermTech Stratum services and believe the addition of clinical tissue bank samples offers an immense time and cost savings benefit to our customers," commented DermTech 2.0 President, Dr.
The DermTech Smart Sticker® provides a 19mm collection area for lesional and non-lesional samples, collecting approximately 1.5mg of representative stratum corneum tissue, eliminating the need for often hard to obtain surgical biopsies in clinical research studies. Once collected, the sample does not require fixation or refrigeration and preserves genomic and proteomic material from the skin for up to 15 days at room temperature and more than a year when stored at -80C. For additional information on DermTech Stratum, please visit the Stratum website at www.dermtechstratum.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dermtech-2-0-expands-dermtech-stratum-a-non-invasive-skin-genomics-service-offering-302650886.html
SOURCE DermTech LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- After Arrest Controversy, "Empire State Building Couple" Angela Nikolau and Ivan Beerkus to Address Recent Incident on Gosh Live
- Baker Hughes Announces Second-Quarter 2026 Results
- In HelloNation, Pool Expert James White Explains How to Choose the Right Pool Finish and Tile for Georgia Heat, Maintenance, and Long-Term Durability
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share